| Bioactivity | SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload for ADCs. | |||||||||
| Invitro | SGD-1882 is the cytotoxic payload undergoing clinical evaluation for anti-CD33 and anti-CD70 conjugates[1]. SGD-1882 is not an MDR1 substrate, and SGN-CD33A is conjugated to the SGD-1882. SGN-CD33A can kill MDR1 expressing CD33 positive AML patient samples and is currently in Phase I[2]. | |||||||||
| Name | SGD-1882 | |||||||||
| CAS | 1222490-34-7 | |||||||||
| Formula | C42H39N5O7 | |||||||||
| Molar Mass | 725.79 | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
SGD-1882
CAS: 1222490-34-7 F: C42H39N5O7 W: 725.79
SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload fo
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.